|
Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Clinical research trials and Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma. Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma clinical trial. Participants oftentimes recieve the finest healthcare available for their Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma  Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
For Condition: stage 4A adult soft tissue sarcoma,stage 3 adult soft tissue sarcoma,stage 4B adult soft tissue sarcoma,localized osteosarcoma,stage 2C adult soft tissue sarcoma,metastatic osteosarcoma
Status: No longer recruiting
Sponsor(s): Herbert Irving Comprehensive Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Interferon alfa may interfere with the growth of cancer cells. Combining interferon alfa and thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa and thalidomide in treating patients who have undergone surgery for soft tissue sarcoma or bone sarcoma.
Details: OBJECTIVES: - Determine the efficacy of interferon alfa and thalidomide, in terms of time to disease progression, in patients with surgically resected high-risk soft tissue sarcoma or bone sarcoma. - Determine the incidence of metastatic disease and overall survival in patients treated with this regimen. - Determine the clinical and laboratory toxic effects and the tolerability of this regimen in these patients. OUTLINE: Patients receive interferon alfa subcutaneously three times a week on weeks 1-60 and oral thalidomide once daily on weeks 13-60 in the absence of disease progression or unacceptable toxicity. Patients are followed every 6 weeks for at least 2 years. PROJECTED ACCRUAL: A total of 20-48 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed primary or metastatic soft tissue sarcoma or bone sarcoma at high risk of recurrence - Grade III-IV tumor greater than 8 cm - Grade III-IV primary tumor greater than 5 cm with positive surgical margins - Grade III-IV primary tumor greater than 5 cm with distant metastases resected within 1 year of primary surgery - No more than 8 weeks since prior surgical resection of primary or metastatic disease - Ineligible for other high priority national or institutional study PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - SWOG 0-2 Life expectancy: - More than 2 months Hematopoietic: - WBC greater than 3,000/mm^3 - Neutrophil count at least 1,500/mm^3 - Platelet count greater than 70,000/mm^3 - Hemoglobin at least 10.0 g/dL Hepatic: - Bilirubin less than 2.0 mg/dL - SGOT or SGPT less than 3 times upper limit of normal (ULN)* - Alkaline phosphatase less than 3 times ULN* - No decompensated liver disease - No autoimmune hepatitis - No coagulation disorders NOTE: * Unless due to metastatic disease Renal: - Creatinine normal Cardiovascular: - No history of severely debilitating cardiovascular disease - No unstable angina - No uncontrolled congestive heart failure - No thrombophlebitis Pulmonary: - No history of severely debilitating pulmonary disease - No chronic obstructive pulmonary disease - No pulmonary embolism Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 forms of effective contraception for 4 weeks before, during, and for 4 weeks after study - No acute infection requiring systemic antibiotics - No prior hypersensitivity to interferon alfa or any component of the injection - No diabetes mellitus prone to ketoacidosis - No severe myelosuppression - No history of autoimmune disease - No pre-existing thyroid abnormalities with thyroid function that cannot be maintained in the normal range - No clinically significant retinal abnormalities - No other serious medical or psychiatric illness that would preclude study - No prior malignancy except curatively treated carcinoma in situ of the cervix or skin cancer PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - Prior systemic chemotherapy allowed Endocrine therapy: - Not specified Radiotherapy: - Prior radiotherapy allowed Surgery: - See Disease Characteristics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
RobertTaub, Study Chair, Columbia Presbyterian Medical Center
Herbert Irving Comprehensive Cancer Center
New York City, New York, 10032
United States
Additional Information:
Study ID Numbers: CDR0000069028; NCI-G01-2024,CPMC-IRB-13887
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00026416
Other Metastatic Osteosarcoma Studies:
1. Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
2. O6-benzylguanine and Carmustine in Treating Patients With Recurrent, Metastatic, or Locally Advanced Soft Tissue Sarcoma
3. Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
4. Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
5. Irinotecan in Treating Patients With Stage IV or Recurrent Soft Tissue Sarcoma
Related Studies:
Other metastatic osteosarcoma Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Interferon alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma
|
|
|
|
|
|
|
|
